
EquitySector - HealthcareVery High Risk
Regular
NAV (19-Dec-25)
Returns (Since Inception)
Fund Size
₹6,460 Cr
Expense Ratio
1.87%
ISIN
INF109KC1GE9
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
12 Jul 2018
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+2.23%
— (Cat Avg.)
3 Years
+27.53%
+22.80% (Cat Avg.)
5 Years
+17.82%
+15.57% (Cat Avg.)
Since Inception
+20.45%
— (Cat Avg.)
| Equity | ₹6,311.53 Cr | 97.70% |
| Others | ₹148.29 Cr | 2.30% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹828.54 Cr | 12.83% |
| Dr Reddy's Laboratories Ltd | Equity | ₹634.02 Cr | 9.81% |
| Cipla Ltd | Equity | ₹516.67 Cr | 8.00% |
| Divi's Laboratories Ltd | Equity | ₹482.98 Cr | 7.48% |
| Aurobindo Pharma Ltd | Equity | ₹390.15 Cr | 6.04% |
| Lupin Ltd | Equity | ₹368.47 Cr | 5.70% |
| Mankind Pharma Ltd | Equity | ₹325.27 Cr | 5.04% |
| Alkem Laboratories Ltd | Equity | ₹244.06 Cr | 3.78% |
| Syngene International Ltd | Equity | ₹191.65 Cr | 2.97% |
| Cohance Lifesciences Ltd | Equity | ₹173.16 Cr | 2.68% |
| Zydus Lifesciences Ltd | Equity | ₹166 Cr | 2.57% |
| Treps | Cash - Repurchase Agreement | ₹143.75 Cr | 2.23% |
| Biocon Ltd | Equity | ₹142.14 Cr | 2.20% |
| Thyrocare Technologies Ltd | Equity | ₹139.02 Cr | 2.15% |
| Alembic Pharmaceuticals Ltd | Equity | ₹119.41 Cr | 1.85% |
| Medi Assist Healthcare Services Ltd | Equity | ₹102.82 Cr | 1.59% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹102.51 Cr | 1.59% |
| Gland Pharma Ltd | Equity | ₹101.16 Cr | 1.57% |
| Blue Jet Healthcare Ltd | Equity | ₹90.96 Cr | 1.41% |
| Pfizer Ltd | Equity | ₹90.03 Cr | 1.39% |
| Medplus Health Services Ltd | Equity | ₹86.63 Cr | 1.34% |
| Metropolis Healthcare Ltd | Equity | ₹84.61 Cr | 1.31% |
| Fine Organic Industries Ltd Ordinary Shares | Equity | ₹75.29 Cr | 1.17% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹73.73 Cr | 1.14% |
| Star Health and Allied Insurance Co Ltd | Equity | ₹72.58 Cr | 1.12% |
| Windlas Biotech Ltd | Equity | ₹67.21 Cr | 1.04% |
| Anthem Biosciences Ltd | Equity | ₹66.81 Cr | 1.03% |
| Shilpa Medicare Ltd | Equity | ₹65.78 Cr | 1.02% |
| Aarti Drugs Ltd | Equity | ₹61.75 Cr | 0.96% |
| Hikal Ltd | Equity | ₹59.12 Cr | 0.92% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹53.9 Cr | 0.83% |
| Senores Pharmaceuticals Ltd | Equity | ₹52.79 Cr | 0.82% |
| AstraZeneca Pharma India Ltd | Equity | ₹49.65 Cr | 0.77% |
| FDC Ltd | Equity | ₹49.63 Cr | 0.77% |
| Rubicon Research Ltd | Equity | ₹47.33 Cr | 0.73% |
| Laxmi Dental Ltd | Equity | ₹45.84 Cr | 0.71% |
| Procter & Gamble Health Ltd | Equity | ₹40.9 Cr | 0.63% |
| Sun Pharma Advanced Research Co Ltd | Equity | ₹40.29 Cr | 0.62% |
| Akums Drugs and Pharmaceuticals Ltd | Equity | ₹8.68 Cr | 0.13% |
| Cash Margin - Derivatives | Cash - Collateral | ₹8.41 Cr | 0.13% |
| Net Current Assets | Cash | ₹-3.87 Cr | 0.06% |
Large Cap Stocks
51.42%
Mid Cap Stocks
13.16%
Small Cap Stocks
31.35%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹6,163.66 Cr | 95.42% |
| Basic Materials | ₹75.29 Cr | 1.17% |
| Financial Services | ₹72.58 Cr | 1.12% |
Standard Deviation
This fund
15.69%
Cat. avg.
16.00%
Lower the better
Sharpe Ratio
This fund
1.20
Cat. avg.
0.94
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.69
Higher the better
Since May 2020
Since July 2022
ISIN INF109KC1GE9 | Expense Ratio 1.87% | Exit Load 1.00% | Fund Size ₹6,460 Cr | Age 7 years 5 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹11,11,127 Cr
Address
3rd Floor, Hallmark Business Plaza, Mumbai, 400 051
Your principal amount will be at Very High Risk


EquitySector - HealthcareVery High Risk
Regular
NAV (19-Dec-25)
Returns (Since Inception)
Fund Size
₹6,460 Cr
Expense Ratio
1.87%
ISIN
INF109KC1GE9
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
12 Jul 2018
Your principal amount will be at Very High Risk

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+2.23%
— (Cat Avg.)
3 Years
+27.53%
+22.80% (Cat Avg.)
5 Years
+17.82%
+15.57% (Cat Avg.)
Since Inception
+20.45%
— (Cat Avg.)
| Equity | ₹6,311.53 Cr | 97.70% |
| Others | ₹148.29 Cr | 2.30% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹828.54 Cr | 12.83% |
| Dr Reddy's Laboratories Ltd | Equity | ₹634.02 Cr | 9.81% |
| Cipla Ltd | Equity | ₹516.67 Cr | 8.00% |
| Divi's Laboratories Ltd | Equity | ₹482.98 Cr | 7.48% |
| Aurobindo Pharma Ltd | Equity | ₹390.15 Cr | 6.04% |
| Lupin Ltd | Equity | ₹368.47 Cr | 5.70% |
| Mankind Pharma Ltd | Equity | ₹325.27 Cr | 5.04% |
| Alkem Laboratories Ltd | Equity | ₹244.06 Cr | 3.78% |
| Syngene International Ltd | Equity | ₹191.65 Cr | 2.97% |
| Cohance Lifesciences Ltd | Equity | ₹173.16 Cr | 2.68% |
| Zydus Lifesciences Ltd | Equity | ₹166 Cr | 2.57% |
| Treps | Cash - Repurchase Agreement | ₹143.75 Cr | 2.23% |
| Biocon Ltd | Equity | ₹142.14 Cr | 2.20% |
| Thyrocare Technologies Ltd | Equity | ₹139.02 Cr | 2.15% |
| Alembic Pharmaceuticals Ltd | Equity | ₹119.41 Cr | 1.85% |
| Medi Assist Healthcare Services Ltd | Equity | ₹102.82 Cr | 1.59% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹102.51 Cr | 1.59% |
| Gland Pharma Ltd | Equity | ₹101.16 Cr | 1.57% |
| Blue Jet Healthcare Ltd | Equity | ₹90.96 Cr | 1.41% |
| Pfizer Ltd | Equity | ₹90.03 Cr | 1.39% |
| Medplus Health Services Ltd | Equity | ₹86.63 Cr | 1.34% |
| Metropolis Healthcare Ltd | Equity | ₹84.61 Cr | 1.31% |
| Fine Organic Industries Ltd Ordinary Shares | Equity | ₹75.29 Cr | 1.17% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹73.73 Cr | 1.14% |
| Star Health and Allied Insurance Co Ltd | Equity | ₹72.58 Cr | 1.12% |
| Windlas Biotech Ltd | Equity | ₹67.21 Cr | 1.04% |
| Anthem Biosciences Ltd | Equity | ₹66.81 Cr | 1.03% |
| Shilpa Medicare Ltd | Equity | ₹65.78 Cr | 1.02% |
| Aarti Drugs Ltd | Equity | ₹61.75 Cr | 0.96% |
| Hikal Ltd | Equity | ₹59.12 Cr | 0.92% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹53.9 Cr | 0.83% |
| Senores Pharmaceuticals Ltd | Equity | ₹52.79 Cr | 0.82% |
| AstraZeneca Pharma India Ltd | Equity | ₹49.65 Cr | 0.77% |
| FDC Ltd | Equity | ₹49.63 Cr | 0.77% |
| Rubicon Research Ltd | Equity | ₹47.33 Cr | 0.73% |
| Laxmi Dental Ltd | Equity | ₹45.84 Cr | 0.71% |
| Procter & Gamble Health Ltd | Equity | ₹40.9 Cr | 0.63% |
| Sun Pharma Advanced Research Co Ltd | Equity | ₹40.29 Cr | 0.62% |
| Akums Drugs and Pharmaceuticals Ltd | Equity | ₹8.68 Cr | 0.13% |
| Cash Margin - Derivatives | Cash - Collateral | ₹8.41 Cr | 0.13% |
| Net Current Assets | Cash | ₹-3.87 Cr | 0.06% |
Large Cap Stocks
51.42%
Mid Cap Stocks
13.16%
Small Cap Stocks
31.35%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹6,163.66 Cr | 95.42% |
| Basic Materials | ₹75.29 Cr | 1.17% |
| Financial Services | ₹72.58 Cr | 1.12% |
Standard Deviation
This fund
15.69%
Cat. avg.
16.00%
Lower the better
Sharpe Ratio
This fund
1.20
Cat. avg.
0.94
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.69
Higher the better
Since May 2020
Since July 2022
ISIN INF109KC1GE9 | Expense Ratio 1.87% | Exit Load 1.00% | Fund Size ₹6,460 Cr | Age 7 years 5 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹11,11,127 Cr
Address
3rd Floor, Hallmark Business Plaza, Mumbai, 400 051
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments